ESR1 and endometrial cancer: However, it has also been found that GR is associated with poor prognosis of endometrial cancer, GR can increase the invasiveness of endometrial cancer cells with high expression of estrogen receptor (ER), and Dex and estradiol (E2) can promote the growth of endometrial cancer cells after co-treatment (Vahrenkamp et al., 2018).